Our Blog

On September 1, 2026, the FDA published a coordinated set of warning letters targeting five online peptide vendors. The sweep signals that the agency is shifting from case-by-case enforcement to sector-wide scrutiny — and that a "research use only" disclaimer is no longer a regulatory shield. Here is what the letters actually say, which vendors and products were named, and what it means for labs sourcing peptides today.

Copper peptide serums have been a skincare staple for years, but a new trend has emerged: people are drawing GHK-Cu into syringes and injecting it at home in pursuit of firmer skin, thicker hair, and slower aging. Here's what the research actually supports, what remains unknown, and why sourcing quality matters for anyone studying this compound.

On September 1, 2026, Rep. Nancy Mace introduced the PEPTIDES for Veterans Act, a bill directing the Department of Veterans Affairs to formally study peptide-based therapies for veterans receiving VA care. Here's what the bill actually does, and doesn't do, for the research community.

Peptides like BPC-157, TB-500, MOTS-c, KPV, epitalon, and semax have become some of the most searched compounds in longevity and biohacking circles. Social media has fueled claims that they speed healing, improve sleep, build muscle, and boost energy. But according to cancer researchers, the evidence behind many of these claims is thin, and there's an open scientific question that gets far less attention than the hype: could some peptides affect cancer risk?

An Australian lab that now spends half its time analyzing peptides bought online has found that black-market vials of a popular weight-loss peptide are just as likely to be overdosed as underdosed. The results add a new dimension to the safety debate around unapproved peptides and underscore why verified sourcing matters.

Peptides are being marketed on TikTok as a shortcut to a younger, sharper-looking face. A pharmaceutical sciences researcher explains why the hype is running well ahead of the evidence, and why sourcing and safety data matter more than ever.

A new Tampa Bay Times report finds that peptides have become one of Florida's fastest-growing health trends, with social media influencers driving demand for compounds marketed to ease joint pain, speed weight loss, and improve sleep. Compounding pharmacists like Dr. David Pino say order volumes have surged, raising fresh questions about oversight, purity, and who's actually formulating what people are injecting.

President Trump has picked Dr. Heidi Overton, a physician and White House health policy aide, as his nominee to lead the FDA. If confirmed by the Senate, she would inherit one of the agency's most closely watched open questions: what happens next for peptides like BPC-157 and TB-500 after this summer's advisory panel vote.

Peptides are everywhere on social media, but most of the unapproved products behind the hype have never been checked for what's actually in the vial. A new public-health review breaks down the safety gaps regulators are racing to close, and why sourcing verification matters more than ever.

Australian doctors are investigating a seventh case of acute liver toxicity linked to black-market peptides sold as retatrutide. Here's what the cluster reveals about counterfeit contamination and why batch-specific testing isn't optional.

A reconstituted FDA advisory panel just overruled its own career scientists to back six peptides for compounding. Here's what actually changed, what didn't, and why verified sourcing still matters most.

Delta sleep-inducing peptide, or DSIP, has become one of the more talked-about compounds in 2026's sleep-and-recovery corner of the peptide world. Interest has outpaced the science, though, and much of what circulates online blurs decades-old animal data with modern marketing claims. Here's a clear look at what DSIP actually is, what the current research does and doesn't support, and why sourcing and purity matter for anyone studying this peptide.

GHK-Cu is a naturally occurring copper-binding tripeptide that has drawn growing interest in dermatology and wound-care research. As demand for peptide-based skin treatments keeps climbing in 2026, it's worth separating what the science actually demonstrates from what's still speculative. Here's a look at what GHK-Cu is, what the current research shows, where the evidence runs out, and why sourcing and purity matter more than ever for anyone studying this compound.

U.S. Customs and Border Protection has flagged a sharp rise in seized peptide shipments moving through international mail facilities and ports of entry in 2026, a trend regulators tie to surging consumer demand for weight-loss and wellness peptides. For the research community, the enforcement data underscores a persistent problem: as demand climbs, so does the incentive to counterfeit. Here's what the seizure trends show, why counterfeits are proliferating, and how legitimate researchers can protect the integrity of their work.

Eli Lilly has filed six lawsuits against wellness and compounding vendors it accuses of selling retatrutide, its unapproved obesity drug candidate, to consumers under the guise of "research use only" peptide sales. Here's what the lawsuits allege and what they signal for the broader research peptide industry.

A major telehealth brand just signaled that peptides are going mainstream. Here's what Hims & Hers' 2026 peptide launch means for the research community and quality-focused buyers.

Peptides are everywhere in wellness culture right now, promoted for everything from muscle building to weight loss to smoother skin. But Stanford Medicine researchers say the excitement has outpaced the evidence. In a recent breakdown of the trend, pathology professors Katrin Svensson and Jonathan Long laid out what's actually known, what isn't, and why the biggest danger for most people isn't the peptide itself. It's where it came from.

When you're purchasing research peptides, one number matters most: purity. But what does "99.1% pure" actually mean? And how do you know a certificate of analysis (COA) is legitimate? In this guide, we'll walk you through peptide quality standards, how purity is measured, and what red flags to watch for when sourcing research-grade compounds.

A 2026 market-news look at West Virginia University pharmacy experts' call for stronger evidence behind the multibillion-dollar peptide industry, and why third-party-verified sourcing matters most for anyone doing research today.

BPC-157 remains one of the most discussed compounds in the peptide research community, but interest in it has outpaced the published science. Here's what the current evidence actually shows, and why purity and testing matter more for this peptide than most.

Tirzepatide is best known for its glucose- and weight-lowering effects, but a newly published study adds evidence for another benefit: a real reduction in serious cardiovascular events. Published in The British Medical Journal, it's one of the largest real-world looks yet at how tirzepatide performs on cardiovascular outcomes outside a clinical trial setting.

Peptides are prized for their ability to drive specific biological processes like bone formation and tissue repair, but their small size has always worked against them in drug delivery: once placed in water-rich materials like hydrogels, they tend to diffuse away long before healing is complete. A new Rice University study, published in Cell Biomaterials, offers a surprisingly simple fix.

Harvard Health Publishing recently examined the fast-growing world of injectable peptides, from FDA-approved medications like insulin and GLP-1 drugs to the unregulated compounds sold online for research and personal use. Their findings offer a useful checkpoint for anyone following the peptide space, including everyone in our own research community.

A new nonprofit is building the first peptide-specific accreditation standards for compounding and sourcing, just as regulators weigh whether to expand access to several popular research peptides.

The FDA advisory panel's vote to ease restrictions on six peptides made headlines this week. But the vote wasn't as clear-cut as the headlines suggest. Behind the scenes, FDA's own scientific staff recommended against it, several panel members have documented industry ties, and the peptides in question are already circulating on the unregulated gray market. Here's what the coverage is missing.

Last month's FDA advisory panel vote on peptide compounding made headlines everywhere — but it's created almost as much confusion as clarity. Here's what actually changed, what hasn't, and what to expect next.

With regulatory attention on peptide purity and sourcing higher than ever, knowing how to evaluate a supplier yourself is one of the most useful skills a researcher can have. Here are five warning signs that should make you think twice before ordering.

A look at the FDA's July 2026 compounding-committee vote on six popular peptides, the safety concerns it has raised among the agency's own scientists and patient-safety groups, and why verified, lab-tested sourcing still matters most.

Many research protocols call for combining more than one peptide at a time, but stacking introduces its own set of variables beyond what a single-compound study requires. This guide covers the basics of peptide stacking: why researchers combine compounds, how to think about complementary mechanisms, timing and injection site considerations when multiple peptides are in use, and the documentation habits that keep a multi-compound protocol interpretable.

Reconstituting and dosing a peptide correctly only gets a researcher halfway there — the injection itself matters just as much. This guide covers subcutaneous injection basics for research peptides: choosing an appropriate site, needle gauge and length considerations, site rotation to avoid tissue irritation, and the common technique mistakes that can affect a study's consistency.

Even a perfectly reconstituted peptide can lose potency if it isn't stored correctly afterward. Temperature swings, light exposure, and simple time all affect how long a peptide solution stays viable for research use. This guide breaks down what actually degrades peptides in storage, how to store both lyophilized and reconstituted vials correctly, and how to recognize the warning signs of a peptide that's gone bad.

Getting the dose right starts with getting the math right. Every research peptide vial carries a concentration, and translating that number into an accurate volume for a syringe is a skill every researcher needs to be comfortable with. This guide walks through the core dosing formula, a worked example, and the most common calculation mistakes to avoid.

A Certificate of Analysis (COA) is the single most important document that comes with a research peptide order, yet it's also one of the most overlooked. Knowing how to read one — and what to look for — turns an unfamiliar lab report into a clear signal of quality and identity. Here's a practical breakdown of what every COA should tell you.

Reconstituting a lyophilized peptide correctly is one of the most important steps in any research protocol. Use too much or too little bacteriostatic water, and your concentration math (and your results) can be thrown off before you even start. Here's a clear walkthrough of the process our research team follows.

Relocating for a conference, shipping samples between labs, or just moving vials from the freezer to the bench: every step outside cold storage puts peptide integrity at risk. Here's what our research team looks at when planning safe transport for temperature-sensitive compounds.

This week's reporting on compounded GLP-1 products raises a question that goes beyond weight-loss injections: how do you know a compounded peptide is chemically what it claims to be? Stanford Medicine clinicians and independent lab analyses are documenting real gaps — unapproved salt forms, undisclosed additives, and even newly formed molecules that don't exist in the approved drug. Here's what the research actually found, and why verified sourcing is the real answer.

While everyone's been focused on which peptides made this week's FDA advisory vote, a quieter story has been unfolding alongside it: the agency's own scientists recommended against every peptide under review, and now patient safety groups are formally warning that the panel's decision came without the evidence needed to justify it. Here's what ECRI, ISMP, and the Partnership for Safe Medicines actually said, and what it means for anyone buying peptides today.

While everyone's been watching the FDA's advisory committee vote, a new Washington Post investigation points to a bigger, quieter risk: the medspas and wellness clinics actually injecting peptides into consumers face less regulatory oversight than your neighborhood restaurant. Here's what the investigation found, why the gap exists, and what it means for anyone buying peptides today.

For months, social media has insisted that Robert F. Kennedy Jr. already "legalized" a wave of popular research peptides. This week's FDA advisory committee vote added fuel to that story, but the actual paper trail tells a more complicated tale. Here's what's really changed, what's still just talk, and what it means if you're buying peptides today.

This week's FDA Pharmacy Compounding Advisory Committee meeting ended with six peptides recommended for the agency's 503A Bulk Drug Substances List and one turned away. The vote made headlines, but the fine print matters more than the tally. Here is what the committee actually decided, what it does not decide, and why sourcing still matters no matter how the FDA rules.

An FDA advisory panel's split vote on peptide compounding sent Hims & Hers Health shares swinging Thursday, as Wall Street analysts weighed a potential multi-billion dollar telehealth opportunity against lingering safety concerns raised by the agency's own scientists.

Politico's reporting on this week's FDA advisory vote reveals a story bigger than which peptides made the list. It shows a panel reshaped by new appointees, FDA scientists warning they have no guardrails left to apply, and a lobbying fight that now moves to Secretary Robert F. Kennedy Jr.'s desk.

A two-day FDA advisory hearing wrapped up July 24, 2026 with a split decision: six peptides, including BPC-157 and TB-500, were recommended for a pharmacy compounding list, while a seventh, emideltide, was turned away over thin safety data.

A 2026 market-news look at this week's FDA Pharmacy Compounding Advisory Committee vote on BPC-157, TB-500, KPV, and MOTS-c, the additional peptides up for a vote today, and what it could mean for the research peptide supply chain.

A 2026 market-news look at Eli Lilly's newest Phase 3 results for retatrutide, the triple GLP-1/GIP/glucagon peptide now headed toward an FDA biologics application, and what its cardiometabolic data could mean for the next wave of peptide-based obesity research.

A 2026 market-news look at Ascletis Pharma's ASC36_35 fixed-dose peptide combination, its preclinical weight-loss data against the eloralintide/tirzepatide combo, and what once-monthly amylin-GLP-1/GIP co-formulations could mean for the next generation of peptide-based obesity research.

A 2026 market-news look at the FDA's newly expanded Pharmacy Compounding Advisory Committee panel and a fresh national poll on legal peptide access, ahead of this week's vote on seven research compounds, and why verified sourcing matters no matter how the vote goes.

A new Bloomberg investigation, citing blockchain analytics firm Chainalysis, reports that gray-market peptide vendors collected $32 million in cryptocurrency during the first quarter of 2026 alone, a 700% jump from a year earlier. The findings point to a fast-growing shadow economy built around unverified overseas suppliers who accept only Bitcoin because banks and card networks won't process payments for compounds marketed as research chemicals not intended for human use. Here's what the data shows, why buyers are turning to crypto, and why verified, third-party-tested sourcing remains the safer path for legitimate research.

Researchers at the University of Bonn and the Research Center Borstel, Leibniz Lung Center have identified a previously unknown way a synthetic peptide can quiet an overactive immune response. Published in Advanced Science, the study shows that the membrane-active peptide Pep19-2.5 binds directly to human immune cell membranes and blocks activation of the NLRP3 inflammasome, the molecular switch behind chronic airway inflammation in allergic asthma. The findings point to a new pharmacological strategy for regulating inflammation and add to growing research into peptides as precision tools for immune modulation.

A new pilot study from the University of Connecticut, published in Frontiers in Nutrition, found that four weeks of collagen peptide supplementation improved bone-formation biomarkers and reduced inflammation in female runners. The research adds to growing evidence that collagen peptides, long known for skin and joint benefits, may also play a protective role in bone remodeling for a population historically understudied in this area.

A 2026 market-news look at a new Sermo physician survey showing rising peptide misinformation and self-prescribing among US patients, and why documented, third-party-verified sourcing matters more than ever for research use.

A 2026 market-news look at Samsung Biologics' $2 billion acquisition of PolyPeptide Group, the largest M&A in Korean pharma and biotech history, and what the deal signals about surging industrial demand for peptide manufacturing and verified purity in research supply chains.

A 2026 market-news look at NOLA.com's deep dive into the peptide craze — from GLP-1 breakthroughs to gray-market self-injection — and why physicians say sourcing and quality control matter more than the hype.

A 2026 market-news look at why endocrinologists are urging caution on the peptide supplement boom, what the science actually supports, and why verified sourcing matters more than ever for anyone working with research peptides.

A 2026 market-news look at the American Pharmacists Association's formal comments to the FDA ahead of this month's Pharmacy Compounding Advisory Committee meeting, why the group is warning about black and gray market peptides, and what verified sourcing means for research labs.

A 2026 research-news look at a Peking University-led peptide vaccine that trained the immune system to neutralize PCSK9, lowering LDL cholesterol in mouse models, and what an active vaccine approach could mean for the future of peptide-based cardiovascular research.

A 2026 market-news look at Merck's newly FDA-approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, and what its macrocyclic peptide design means for the future of peptide drug research and sourcing.

A 2026 research-news look at a newly discovered natural peptide aptamer that switches between two unrelated protein targets depending on the surrounding metal ion, and what the finding means for future protein-recognition and biosensor research.

A 2026 market-news look at the newly launched global Phase II trial of CY-101, a synthetic peptide immunotherapy for adrenocortical carcinoma, and what growing clinical validation of peptide-based immunotherapy means for the research community.

A 2026 market-news look at the FDA's April 23 removal of twelve peptides, including BPC-157, TB-500, GHK-Cu, MOTS-c, Epitalon, Semax, and KPV, from its Category 2 restricted-compounding list, and why the shift doesn't change the purity standards research labs should demand.

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone widely used in receptor-binding and pigmentation-pathway research. This guide covers its research background, mechanism of interest, and purity standards for laboratory use.

ALCAR (Acetyl-L-Carnitine) is a widely studied acetylated amino acid derivative used in mitochondrial and neurocognitive research. This guide covers its research background, mechanism of interest, and purity standards for laboratory use.

A cyclized Cecropin A analog called OMN6 wins ~€8M in EU funding and enters Phase IIa trials targeting carbapenem-resistant Acinetobacter baumannii pneumonia.

A new npj Microgravity study scores 26 peptide-based medications for feasibility of recombinant in-situ production during multi-year space missions.

A new hybrid quantum-classical AI system generated lab-validated peptide binders for understudied HLA immune targets, per a July 2026 preprint from TU Denmark and ORCA Computing.

Penn and CUHK researchers unveil TD3B, an AI framework that designs peptides predicted to activate or block GPCR targets, advancing peptide research and drug discovery tools.

A new JAMA Viewpoint says injectable peptides now sit in a regulatory grey zone. Here's what it means for research sourcing, purity, and compliance.

The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to weigh seven peptides for the 503A Bulks List. Here's what it means for research.

The peptide therapeutics market is experiencing powerful momentum in 2026. According to Grand View Research, the global market stood at approximately $140.9 billion in 2025 and is expected to reach $164.0 billion in 2026, on track to hit $294.6 billion by 2033 at a compound annual growth rate (CAGR) of 8.7%.

A 2026 market-news look at why Thymosin Alpha-1 is drawing fresh research interest for immune health and healthy aging, and what the current evidence does and doesn't support.

A 2026 market-news look at KPV, the alpha-MSH-derived tripeptide included in the FDA's upcoming July 23-24 Pharmacy Compounding Advisory Committee review, and what the research says about its proposed anti-inflammatory mechanisms.

A 2026 market-news look at why self-directed peptide use is climbing, what clinicians and major outlets are warning about unsupervised dosing, and how researchers can reduce risk through verified sourcing and rigorous protocols.

A 2026 market-news look at why peptides have become the year's defining longevity and biohacking trend, what physicians are warning about DIY use, and why verified sourcing matters more than ever.

A 2026 market-news roundup of the peer-reviewed and preclinical research behind BPC-157, its current regulatory status, and the purity standards that keep tissue-repair research reproducible.

A 2026 market-news look at how fast the research peptide industry is growing, and why the widening gap between third-party HPLC-verified compounds and unverified gray-market imports matters more than the growth numbers themselves.

A 2026 research-use-only deep dive into MOTS-c, SS-31, and the mitochondrial peptides driving longevity and cellular-energy research, plus the handling and third-party purity standards that keep results reproducible.

A 2026 research-use-only comparison of the triple agonist Retatrutide and the dual agonist Tirzepatide: receptor profiles, how each is studied in metabolic models, and the purity standards that support reproducible results.

A 2026 research-use-only overview of how BPC-157 is studied across tissue-repair models, its proposed mechanisms, and the purity standards that support reproducible results.

Epithalon (also spelled epitalon) is a synthetic tetrapeptide studied for its proposed effects on telomerase activity and cellular aging. This guide explains what the peptide is, how it's investigated in longevity and chronobiology research models, and the purity and storage standards every lab should verify. For laboratory research use only.

GHK-Cu is one of the most studied copper peptides in regenerative research. This guide breaks down its role in collagen synthesis, skin remodeling, and wound-healing pathways, plus reconstitution, storage, and purity standards every researcher should verify. For laboratory research use only.

Research peptides are short-chain amino acid sequences designed for scientific investigation. Unlike pharmaceutical drugs, they are produced for laboratory research only and must not be used on humans or animals. Understanding their purity standards, storage requirements, and procurement sources is essential for credible research outcomes.

NAD+ and NMN are two of the most studied molecules in longevity and cellular-energy research, but they play different roles in the NAD+ pathway. This guide compares their mechanisms, research applications, and stability so labs can choose the right compound and verify purity before study. For laboratory research use only.

From BPC-157 and TB-500 to Epithalon, GHK-Cu, and MOTS-c, longevity peptides are among the fastest-growing areas of preclinical research. This 2026 guide ranks five of the most studied longevity research peptides, what each is investigated for, and the purity standards labs should verify. For laboratory research use only.

BPC-157 and TB-500 are two of the most studied peptides in tissue-repair and recovery research, and they are frequently investigated together as a complementary stack. This guide explains how each peptide works, why researchers pair them, and the purity and storage standards every protocol should verify. For laboratory research use only.